Saito Biotech announced that Shandong Sirui Pharmaceutical Co., Ltd., a holding subsidiary of the company, recently received the “Drug GMP Compliance Inspection Notice” issued by the Shandong Drug Administration, and its API 01 workshop 01 integrated production line has been inspected to meet the requirements of the “Pharmaceutical Production Quality Management Code”. Passing this inspection will help the company maintain stable product quality and production capacity, meet the needs of the relevant pharmaceutical market, and have a positive effect on future development. Pharmaceutical production and sales are affected by various factors and there is uncertainty. Investors are kindly requested to pay attention to investment risks.

Zhitongcaijing · 2d ago
Saito Biotech announced that Shandong Sirui Pharmaceutical Co., Ltd., a holding subsidiary of the company, recently received the “Drug GMP Compliance Inspection Notice” issued by the Shandong Drug Administration, and its API 01 workshop 01 integrated production line has been inspected to meet the requirements of the “Pharmaceutical Production Quality Management Code”. Passing this inspection will help the company maintain stable product quality and production capacity, meet the needs of the relevant pharmaceutical market, and have a positive effect on future development. Pharmaceutical production and sales are affected by various factors and there is uncertainty. Investors are kindly requested to pay attention to investment risks.